Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21) — is cataloged under number PA-06-387 and tied to CFDA assistance listing 93.847, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on May 5, 2006 and last updated on December 5, 2008. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $200,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity is open, but Grants.gov has not published a hard closing date — check the official listing for the current deadline and any posted amendments. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Up to $200,000
Close Date
Not specified
Multiple Receipt Dates - See Link to Full Announcement for details.
Posted
May 5, 2006
Instrument
Grant
Description
-The Pilot and Feasibility Clinical Research Grants Program is designed to support short-term clinical pilot studies and planning activities to help stimulate the translation of promising research developments from the laboratory into clinical practice for diabetes, endocrine and metabolic diseases. -The Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases invites applications for the exploratory/developmental (R21) grant mechanism in selected areas of opportunity within our mission. The intent of this initiative is to encourage researchers to apply novel technologies, develop new tools, biomarkers and model systems, and test innovative concepts of potential diagnostic and therapeutic relevance to diseases within our mission including diabetes and its complications, obesity, endocrine disorders including osteoporosis, and inborn errors of metabolism including cystic fibrosis. The R21 mechanism is intended to encourage exploratory research projects by providing support at the conceptual stages of these projects. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. -Project Period and Award Levels: The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over the two years of the R21 award, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. -This announcement uses the NIH exploratory/developmental grant (R21) award mechanism. -Eligible organizations: For-profit or non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Units of State and local governments; Eligible agencies of the Federal government; Domestic or foreign institutions; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization. -Eligible Project Directors/Principal Investigators (PD/PIs):Any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. -Applicants may submit more than one application, provided they are scientifically distinct. -An R21 is not renewable.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Diabetes, Endocrine, and Metabolic Disease Research
National Institutes of Health
Agency Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |